Who are CytomX Therapeutics's investors?

CytomX Therapeutics's investors include ATEL Ventures, Canaan Partners, Longitude Capital, Pfizer Venture Investments, Wellington Management, OrbiMed, Third Rock Ventures.

How much funding has CytomX Therapeutics raised?

CytomX Therapeutics has disclosed $350.5M raised across 4 of its 5 known rounds.

Where is CytomX Therapeutics headquartered?

CytomX Therapeutics is headquartered in South San Francisco, US.

CytomX Therapeutics

NASDAQ: CTMX

South San Francisco, US · Founded 2010 · 104 employees on LinkedIn · 7 known investors

Find your way into CytomX Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the CytomX Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.

Biotech Healthtech

Founders & leadership

Sean A. McCarthy Chief Executive Officer and ChairmanSean McCarthy is Chief Executive Officer and Chairman of CytomX Therapeutics, which he has led since 2011. He holds a D.Phil. in cancer biology from the University of Oxford, an MBA from UC San Diego's Rady School of Management, and a B.Sc. in biochemistry and pharmacology from King's College London, and brings over 25 years of biotechnology industry experience including prior roles at Millennium Pharmaceuticals and SGX Pharmaceuticals, as well as venture investment experience at Pappas Ventures.

Marcia P. Belvin SVP, Chief Scientific OfficerMarcia Belvin is Chief Scientific Officer at CytomX Therapeutics, where she leads research on the company's protease-activated biologics platform. She previously spent over 13 years at Genentech leading preclinical teams in cancer biology programs, and held discovery roles at Exelixis in oncology and inflammation, with a B.A. from Harvard University and Ph.D. from UC Berkeley.

Dawn BensonSVP, Quality and Product ManufacturingSVP, Quality and Product Manufacturing at CytomX

Wayne ChuChief Medical Officer

Rachael Lester SVP, Chief Business OfficerRachael Lester is Senior Vice President and Chief Business Officer at CytomX, a clinical-stage biopharmaceutical company developing Probody cancer therapeutics. She brings over 20 years of experience in healthcare and biopharma, including corporate strategy, M&A, portfolio planning, new product commercialization, and corporate finance.

Chris Ogden Chief Financial OfficerChief Financial Officer at CytomX

Leslie Robbins SVP, Intellectual PropertyLeslie Robbins is Senior Vice President of Intellectual Property at CytomX, a clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics for cancer. She has worked as corporate and intellectual property counsel in the biotechnology and pharmaceutical industries, serving in both in-house and outside counsel roles.

Stephanie RobertsonSVP, Alliances & Program LeadershipSVP, Alliances & Program Leadership at CytomX

Danielle Olander-Moghadassian Consulting Chief Human Resources OfficerHR and organizational development executive with over 25 years of experience in the life sciences industry. She previously served as Chief Human Resources and Organizational Development Officer at CytomX Therapeutics for nearly 11 years, leading cross-functional initiatives spanning HR, IT, and facilities, and now consults with life sciences companies on people strategy and organizational infrastructure.

Lloyd A. Rowland, Jr.Consulting General Counsel

Mamata GokhaleSVP, Regulatory Affairs

Alejandra CarvajalChief Legal Officer

Investors · 7

ATEL Ventureslisted by ATEL VenturesSan Francisco

How we know: ATEL Ventures's portfolio page · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: the VCSheet dataset · Not right? Tell us

Third Rock VenturesreportedBoston · $100K – $5Mvia Neil Exter · board

How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

$350.5M disclosed across 4 of 5 rounds · 2014–2026

$234Mequity offeringMar 2026
Source ↗

▶$30MraisedAug 2023 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Chris OgdenExecutive Officer
Marcia BelvinExecutive Officer
James MeyersDirector
Alan AshworthDirector
Matthew YoungDirector
Jeff LandauExecutive Officer
Halley GilbertDirector
Wayne ChuExecutive Officer
Elaine JonesDirector
Mani MohindruDirector
Sean McCarthyExecutive Officer, Director
Lloyd RowlandExecutive Officer

Offering amount: $30M
Amount sold: $30M
First sale: Jun 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$70MraisedJun 2015 · 33 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rachel HumphreyDirector
Tim ShannonDirector
Frederick W. GluckDirector
Hoyoung HuhDirector
Elaine V. JonesDirector
Neil ExterDirector
Sean McCarthyExecutive Officer, Director

Offering amount: $70M
Amount sold: $70M
First sale: Jun 2015
Incorporated: Corporation, Delaware, 2010
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$16.5MraisedJan 2015 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Tim ShannonDirector
Frederick W. GluckDirector
Elaine V. JonesDirector
Sean McCarthyExecutive Officer, Director
Neil ExterDirector
Hoyoung HuhDirector

Offering amount: $30M
Amount sold: $16.5M
First sale: Dec 2014
Incorporated: Corporation, Delaware, 2010
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$419Mvaluation at IPOOct 2015 · $12.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

The CytomX Therapeutics mafia →

8 people who came through CytomX Therapeutics went on to found or lead other companies.

Nancy StaglianoCEOFounded Star Therapeutics +1 Timothy ShannonDirectorFounded Quarry Thera Julie GrantBoard ObserverFounded Day One Biopharmaceuticals Charles (Charlie) FuchsBoard Of DirectorsFounded EvolveImmune Therapeutics Krishna PoluChief Medical OfficerFounded Commit Biologics Jeff LandauChief Business Officer and Head of StrategyFounded Stipple Bio Rachel HumphreyMember Board of DirectorsFounded Normunity Tony W. LiangScientist IFounded PTM Therapeutics, Inc.

In the news

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026

Frequently asked questions

What does CytomX Therapeutics do?: CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
Who are CytomX Therapeutics's investors?: CytomX Therapeutics's investors include ATEL Ventures, Canaan Partners, Longitude Capital, Pfizer Venture Investments, Wellington Management, OrbiMed, Third Rock Ventures.
How much funding has CytomX Therapeutics raised?: CytomX Therapeutics has disclosed $350.5M raised across 4 of its 5 known rounds.
Where is CytomX Therapeutics headquartered?: CytomX Therapeutics is headquartered in South San Francisco, US.